{"Exaggerate": "The claim exaggerates the ease of access to hydroxychloroquine and chloroquine after the FDA's revocation of emergency use authorization.", "Contradict fact": "The claim contradicts the fact that the FDA's decision actually makes it more difficult to access the drugs.", "Lack enough support": "The claim lacks enough support to back up its assertion that the FDA's decision removes a potential barrier.", "Problematic assumption": "The claim assumes that the FDA's revocation of emergency use authorization makes it easier to access the drugs, which is a problematic assumption.", "Exist alternative explanation": "The claim fails to consider alternative explanations for the FDA's decision and its impact on access to the drugs."}